Will Haemonetics’ (HAE) Margin Gains and Upbeat Guidance Recast Its Long-Term Growth Narrative?

• Haemonetics Corporation recently reported second-quarter earnings results, revealing sales of US$327.32 million and net income of US$38.68 million, with both basic and diluted earnings per share from continuing operations rising to US$0.81, up from US$0.66 a year earlier.
• Despite a year-over-year decline in revenue, the company achieved expanded gross and operating margins and raised its full-year adjusted EPS guidance, highlighting improved operational efficiency and confidence in future performance.
• Now, we'll explore how Haemonetics' improved profitability and guidance outlook could influence the company's future investment narrative.

Find companies with promising cash flow potential yet trading below their fair value.

Haemonetics Investment Narrative Recap

To be a shareholder in Haemonetics, one must believe in its ability to drive sustained margin expansion and leverage innovation in plasma and hospital products to offset episodic revenue pressures. The company's latest earnings report, with rising profit margins and strengthened guidance despite a year-over-year sales dip, further supports the catalyst of margin improvement, but does not materially change the short-term risk that heightened competition and ongoing execution issues, particularly in the vascular closure business, could weigh on growth.

The launch of the new VASCADE MVP XL venous closure device, announced earlier this year, stands out as relevant given the segment's importance and ongoing competitive challenges. Success with new product launches in interventional technologies remains linked to overcoming execution hurdles, restoring market momentum, and supporting future diversification.

By contrast, investors should not overlook the continued pressure from competitive and legacy players in the vascular closure market...

Read the full narrative on Haemonetics (it's free!)

Haemonetics' narrative projects $1.5 billion revenue and $257.9 million earnings by 2028. This requires 2.6% yearly revenue growth and a $94.6 million increase in earnings from $163.3 million today.

Uncover how Haemonetics' forecasts yield a $76.27 fair value, a 12% upside to its current price.

Exploring Other Perspectives

Three members of the Simply Wall St Community estimate Haemonetics' fair value in a wide span from US$70.70 to US$99.06 per share. While some focus on margin expansion potential, others flag competitive risk in vascular closure as a key issue that could affect outcomes, consider the range of views before deciding where you stand.

Explore 3 other fair value estimates on Haemonetics - why the stock might be worth just $70.70!

Build Your Own Haemonetics Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Haemonetics research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Haemonetics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Haemonetics' overall financial health at a glance.

Want Some Alternatives?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com